Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/54414
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Marathe, Chaitra | en_US |
dc.contributor.author | Bradley, Michelle N. | en_US |
dc.contributor.author | Hong, Cynthia | en_US |
dc.contributor.author | Lopez, Felix | en_US |
dc.contributor.author | Ruiz De Galarreta, Carlos M. | en_US |
dc.contributor.author | Tontonoz, Peter | en_US |
dc.contributor.author | Castrillo, Antonio | en_US |
dc.date.accessioned | 2019-02-18T10:38:52Z | - |
dc.date.available | 2019-02-18T10:38:52Z | - |
dc.date.issued | 2006 | en_US |
dc.identifier.issn | 0021-9258 | en_US |
dc.identifier.uri | http://hdl.handle.net/10553/54414 | - |
dc.description.abstract | The liver X receptors (LXRs) are ligand-dependent transcription factors that have been implicated in lipid metabolism and inflammation. LXRs also inhibit the expression of inflammatory genes in macrophages, including inducible nitric oxide synthase (iNOS). Some of these actions are mediated through LXR antagonism of NF-kappa B activity. The potential for LXRs to positively regulate the expression of anti-inflammatory molecules, however, has not been explored. Here we show that the arginase II (ArgII) gene is a direct target for LXR regulation. ArgII catalyzes the conversion of L-arginine into L-ornithine and urea, leading to the synthesis of polyamines. Expression of ArgII is induced by LXR agonists in macrophage cell lines and primary murine macrophages in a receptor-dependent manner. The ArgII promoter contains a functional LXR response elements that mediates promoter induction by LXR/RXR (retinoid X receptor) in transfection assays. Since ArgII and iNOS utilize a common substrate, induction of ArgII expression has the potential to exert anti-inflammatory effects by shifting arginine metabolism toward polyamine synthesis at the expense of NO production. In support of this hypothesis, we demonstrate that forced expression of ArgII mimics the inhibitory effect of LXR activation on macrophage NO production. Furthermore, inhibition of arginase activity partially reverses the inhibitory effect of LXR agonists on NO production. These studies suggest that regulation of ArgII may contribute to the immunomodulatory effects of LXRs. | en_US |
dc.language | spa | en_US |
dc.publisher | 0021-9258 | |
dc.relation | Saf2005-03270. Los Receptores Lxr y Su Papel en la Respuesta Inflamatoria, Inmunitaria y Apoptótica. | en_US |
dc.relation.ispartof | Journal of Biological Chemistry | en_US |
dc.source | Journal of Biological Chemistry[ISSN 0021-9258],v. 281, p. 32197-32206 | en_US |
dc.subject.other | Interferon Regulatory Factor-3 | |
dc.subject.other | Nitric-Oxide Synthase | |
dc.subject.other | L-Arginine | |
dc.subject.other | Differential Regulation | |
dc.subject.other | Reciprocal Regulation | |
dc.subject.other | Nuclear Receptors | |
dc.subject.other | Lipid-Metabolism | |
dc.subject.other | Mouse Model | |
dc.subject.other | Lxr | |
dc.subject.other | Cholesterol | |
dc.title | The arginase II gene is an anti-inflammatory target of liver X receptor in macrophages | en_US |
dc.type | info:eu-repo/semantics/Article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1074/jbc.M605237200 | en_US |
dc.identifier.scopus | 33845934193 | - |
dc.identifier.isi | 000241414500017 | - |
dc.contributor.authorscopusid | 6507337761 | - |
dc.contributor.authorscopusid | 7202096772 | - |
dc.contributor.authorscopusid | 15755660400 | - |
dc.contributor.authorscopusid | 7202047893 | - |
dc.contributor.authorscopusid | 6602478628 | - |
dc.contributor.authorscopusid | 7003806034 | - |
dc.contributor.authorscopusid | 7007079890 | - |
dc.contributor.authorscopusid | 55445301000 | - |
dc.description.lastpage | 32206 | en_US |
dc.description.firstpage | 32197 | en_US |
dc.relation.volume | 281 | en_US |
dc.type2 | Artículo | en_US |
dc.contributor.daisngid | 4210757 | - |
dc.contributor.daisngid | 2210915 | - |
dc.contributor.daisngid | 750105 | - |
dc.contributor.daisngid | 2864371 | - |
dc.contributor.daisngid | 1664323 | - |
dc.contributor.daisngid | 103250 | - |
dc.contributor.daisngid | 225640 | - |
dc.contributor.wosstandard | WOS:Marathe, C | - |
dc.contributor.wosstandard | WOS:Bradley, MN | - |
dc.contributor.wosstandard | WOS:Hong, C | - |
dc.contributor.wosstandard | WOS:Lopez, F | - |
dc.contributor.wosstandard | WOS:de Galarreta, CMR | - |
dc.contributor.wosstandard | WOS:Tontonoz, P | - |
dc.contributor.wosstandard | WOS:Castrillo, A | - |
dc.date.coverdate | Octubre 2006 | en_US |
dc.identifier.ulpgc | Sí | es |
dc.description.jcr | 5,808 | |
dc.description.jcrq | Q1 | |
dc.description.scie | SCIE | |
item.grantfulltext | none | - |
item.fulltext | Sin texto completo | - |
crisitem.project.principalinvestigator | Castrillo Viguera, Antonio Jesús | - |
crisitem.author.dept | GIR IUIBS: Farmacología Molecular y Traslacional | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | Departamento de Ciencias Clínicas | - |
crisitem.author.dept | GIR IUIBS: Farmacología Molecular y Traslacional | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.orcid | 0000-0003-1167-9787 | - |
crisitem.author.orcid | 0000-0002-2057-2159 | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.fullName | López Blanco, Félix | - |
crisitem.author.fullName | Castrillo Viguera, Antonio Jesús | - |
Appears in Collections: | Artículos |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.